Michael Wyand, DVM, PhD is a biopharmaceutical executive with over twenty-five years experience in managing and building successful product and service oriented life science companies. He is the CEO and Director of Oxeia Biopharmaceuticals, a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction.
An accomplished leader, Dr. Wyand has substantial experience managing drug development and as a corporate officer responsible for communicating corporate strategy and value propositions to company directors, external investors and partners. Dr. Wyand was President/COO of Epirus Biopharmaceuticals after starting as CTO from 2012 to 2016. Prior to that he headed R&D at Percivia, a J&J/DSM joint venture.
Dr. Wyand trained in comparative pathology at Harvard Medical School, received his DVM from Purdue University and his PhD in Pathology from the University of Connecticut. He received a BS in Biology from the University of Connecticut where he graduated with honors as a University Scholar.
Vishal Bansal, M.D. F.A.C.S. is the Chief Scientific Officer and Co-Founder of Oxeia Biopharmaceuticals. Since 2015, Dr. Bansal is a Director of Trauma Surgery at Scripps Mercy Hospital in San Diego.
Dr. Bansal is a clinically active trauma and general surgeon as well as a funded surgical scientist focusing on the physiologic response to brain injury. He has been a principal investigator of three trials in traumatic brain injury. He has nearly 100 peer review publications, book chapters and invited reviews, sits on three national trauma committees, and is a referee for over 25 national and international scientific journals.
Oxeia Biopharmaceuticals is a privately held clinical stage biotech company developing drug treatments for concussion and underlying neuro-metabolic dysfunction. Oxeia has completed phase 2a testing on OXE103, a synthetic human ghrelin, an endogenous hormone. OXE103 freely crosses the blood-brain barrier addressing underlying neuro-metabolic dysfunction and axonal injury. OXE103 uniquely targets the hippocampus region of the brain, an area important for cognition and memory.
Oxeia’s phase 2a study showed robust treatment effect across study endpoints with 85% of OXE103 patients improving while only 33% improved with standard care alone. This was the first time any drug showed meaningful improvement in persistent concussion symptoms. Meaningful improvements were made in the reduction of symptom severity and the quality of life. See: oxeiabiopharma.com and startengine.com/offering/oxeia-biopharma for investment opportunity.
Note: Formal NFL Quarterback Alex Smith couldn't join us as planned due to a sudden illness; in the process of rescheduling for a future show.
Recovery Now is a gathering place for anyone seeking recovery from the challenges of life on life's terms. Guests share their experience, strength, and hope. We discuss useful tools that have helped us lighten the load, of our journey through recovery. More will be revealed. This is a "we" recovery program, because it is in the "we" that we find the new "me". We focus on the four A's of Recovery: Awareness, Acceptance, Action, and Adaptation. This is a place for survivors striving to become thrivers. For that, it takes a good bit of warrior! Your host is Kim Justus, found at inaflash.org
Mehr anzeigen
Weniger anzeigen
Feb 19 20262 Std. und 2 Min.